Imidazopyrazines as Cyclin Dependent Kinase Inhibitors

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F04%3A00035995" target="_blank" >RIV/00216224:14310/04:00035995 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Imidazopyrazines as Cyclin Dependent Kinase Inhibitors

Original language description

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. of formula I [R = H, halo, (un)substituted-aryl, -heteroaryl, -cycloalkyl, etc.; R1 = H, halo or alkyl; R2 = halo, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R3 = H, (un)substituted-aryl, -heteroaryl, -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds., methods of prepg. pharmaceutical formulationscomprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepd. by condensation of 8-chloro-3-methylimidazo[1,2-a]pyrazine with 4-(aminomethyl)pyridine. I possessed excellent CDK inhibitory properties, e.g., II demonstrated an IC50 value of 22.5 uM.

Czech name

—

Czech description

—

Type

P - Patent

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2004

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID

WO 2004026877 A1

Publisher

—

Publisher name

—

Place of publication

—

Publication country

—

Date of acceptance

Apr 1, 2004

Owner name

Schering-Plough

Method of use

A - Výsledek využívá pouze poskytovatel

Usage type

A - K využití výsledku jiným subjektem je vždy nutné nabytí licence